Pharmaceutical Chemistry II. Antifungal Agents. = Antimycotics. Tutorial 1

Similar documents
PHARMACEUTICAL CHEMISTRY II (PHCM672) Lecture 1, Antifungal Drugs (Antimycotics) Dr. Mohammad Abdel-Halim

Fungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell

Antifungal drugs Dr. Raz Muhammed

Antimycotics. November 14, Jan Strojil. Ústav farmakologie LF UP

(Notes on Anti-TB agents are included in the TB syllabus)

ANTIMYCOTIC DRUGS Modes of Action

Antifungal Agents. Polyenes Azoles Allyl and Benzyl Amines Other antifungals

Course content. Chemotherapeutic agents

Antifungal Agents. Prof. Suheil Zmeili Faculty of Medicine Department of Pharmacology University of Jordan

Antifungals, antivirals, antiprotozoals, and anthelmintics

Antimicrobials; antibacterials, antifungals, antiprotozoans, antivirals, and antihelminthics 6

Antifungal resistance mechanisms in pathogenic fungi

Biochemical Targets for Antifungal Chemotherapy

ANTIFUNGAL AGENTS. Alison Clode, DVM, DACVO. Port City Veterinary Referral Hospital Portsmouth, New Hampshire

Itraconazole DIGICON. Composition: MOLECULAR INTRODUCTION

Med Chem 401: Mycology ( Mycology

About the Editor Gerri S. Hall, Ph.D.

Biochemical Targets for Antifungal Chemotherapy

Updated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017

SUSCEPTIBILITY PROFILE OF EMERGING FUNGAL PATHOGENS

Pharmacogenomics of Antifungal Agents

Ali Alabbadi. Sarah Jaar ... Nader

Special features. For personal use only. Not to be reproduced without permission of the editor

Current Options in Antifungal Pharmacotherapy

Medicinal Chemistry I II nd Module Special Section (3) Major Antifungal Drugs

Clinical Practice Guideline Superficial Fungal Infection

Voriconazole. Voriconazole VRCZ ITCZ

Antifungal therapies differences in agents

Antifungal Drugs 35 I. OVERVIEW II. DRUGS FOR SUBCUTANEOUS AND SYSTEMIC MYCOTIC INFECTIONS

Management of fungal infection

Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance

New antifungal agents

Improving Clinical Outcomes in Fungal Infection Control and Management

Introduction. Yeast candida, cryptococcus, trichosporon. Filamentous rhizopus, rhizomucor, mucor. Dimorphic Fungi bl t hi t l

Updates and practical guide on antifungal agents

Current and Emerging Azole Antifungal Agents

Chapter III ANTIVIRAL AND ANTIFUNGAL DRUGS

number Done by Corrected by Doctor د.حامد الزعبي

B. Incorrect! Peginterferon α-2a is used for the treatment of chronic hepatitis B and may be preferable to interferon- α.

The ADME properties of most drugs strongly depends on the ability of the drug to pass through membranes via simple diffusion.

Antibiotics derived from the acetate metabolism

LUZU (luliconazole) external cream

C. albicans C. tropicalis C. parapsilosis C. kefyr C. glabrata C. krusei C. guillermondii C. lusitaniae THERAPY USING ANTIFUNGALS AND ANTIVIRALS

Review Article Antifungal Resistance and New Strategies to Control Fungal Infections

Cigna Drug and Biologic Coverage Policy

No Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany

Challenges and controversies of Invasive fungal Infections

Fungal Infection Pre-Infusion Data

Mycology. Dr. Agoston Ghidan

DISEASES OF FUNGAL ORIGIN

Industrial Toxicology

Review of Newer Antifungal and Immunomodulatory Strategies for Invasive Aspergillosis

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

Drugs dermatological conditions II

MANAGEMENT OF PULMONARY MYCOSIS

Rheem Totah, Office H172M, Ph Office hours MWF 11:30 12:20 or by arrangement

Dr Hamed Alzoubi. Fungal infections

THE TREATMENT OF MYCOSES IN REPTILES: A REVIEW OF ANTIFUNGAL DRUGS

Sumyuktha J., Murali Narasimhan*, Parveen Basher Ahamed

ITRANOX. Composition Each capsule contains :

CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR

Table 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.

Fungal Infection Post-Infusion Data

The incidence of invasive fungal infections

Antifungal resistance in Aspergillus fumigatus

A New Triazole, Voriconazole (UK-109,496), Blocks Sterol Biosynthesis in Candida albicans and Candida krusei

Medical Management of Fungal Sinusitis

number Done by Corrected by Doctor

Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance

Current options of antifungal therapy in invasive candidiasis

ANTIFUNGAL DRUG DISCOVERY: FOCUS ON INCRUSTOPORIN DERIVATIVES

Fungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia

Antifungals and current treatment guidelines in pediatrics and neonatology

MINIREVIEWS. Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance

Antifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?

Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory ZODERM E CREAM. Oxiconazole Nitrate Cream

MINIREVIEW. Combination Antifungal Therapy

Fungal infections and critically ill adults

NEW ANTI-INFECTIVE AGENTS IN 2003 : SPECTRUM AND INDICATIONS. 20th Symposium (spring 2003) Thursday May 22nd 2003

Condition First line Alternative Comments Candidemia Nonneutropenic adults

New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance

IJBCP International Journal of Basic & Clinical Pharmacology

Pharmacology of Antifungal Drugs in Newborns- Rio de Janeiro August 2014

Antifungal Pharmacotherapy

Common Fungi. Catherine Diamond MD MPH

Antifungal Activity of Voriconazole on Local Isolates: an In-vitro Study

Antifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?

Fungal Infections. Alessandro Diana November 22th 2007

I am against to TDM in critically ill patient

Metabolic Changes of Drugs and Related Organic Compounds

FLUCAND HIKMA PHARMACEUTICALS

Pathogens with Intermediate Virulence Dermatophytes opportunistic Pathogens

Medicinal Chemistry 410 Exam #1 February 20, 2009 Name: Med. Chem. #

Case Studies in Fungal Infections and Antifungal Therapy

Case. Fungal infections for the community provider. Case. Case. April 25, 2014 Peter V. Chin-Hong M.D. Infectious Diseases UCSF UCSF

Invasive Fungal Infections in Solid Organ Transplant Recipients

Chemical Control of Septoria Leaf Blotch: history, biological performance, and molecular mode of action of DMI fungicides

Antifungal Update. Candida: In Vitro Antifungal Susceptibility Testing

Transcription:

Pharmaceutical Chemistry II Antifungal Agents = Antimycotics Tutorial 1

1) Give examples of some common fungal infections indicating whether they are rather superficial or systemic. Fungal infections Tinea corporis Tinea capitis Tineaunguium(onychomycosis) Tinea pedis(athlethe s foot) Tinea cruris(jockitch) Candida albicans Cryptococcus neoformans Blastomyces dermatidus Superficial/Systemic Superficial (skin, hair, and nails) Superficial (oral, vaginal, skin and nails )/Systemic Systemic Systemic Aspergillosis Systemic

Drugs Classification of Antifungal 1-Inhibitors of Cell Membrane and its Function A-Drugs affecting cell membrane function Polyenes(Nystatin- Amphotericin B) B-Inhibitors of ergosterolsynthesis 1-Azoles Imidazoles(Clotrimazole, Miconazole, Ketoconazole) Triazoles(Itraconazole, Posaconazole, Fluconazole, Voriconazole) 2-Allylamines Terbanafine, Tolnaftate 3-Morpholines (Amorolfine) Not explained 2- Inhibitors of DNA/RNA Functions Flucytosin - Griseofulvin 3- Inhibitors of Cell Wall Functions Echinocandins (Caspofungin)

Inhibitors of Cell Membrane A-Drugs affecting cell membrane function Polyene antibiotics(nystatin- Amphotericin B) 4

2) Describe the structure of amphotericin B and show how its structure is amphoteric and amphiphilic. Explain its mode of action. Large lactone ring (38 membered) Mycosamine Amnio sugar Carboxylic acid amphoteric: has acidic and basic group Primary amine

2) Describe the structure of amphotericin B and show how its structure is amphoteric and amphiphilic. Explain its mode of action. Hydrophilic Lipophilic Polyene: multiple double bonds amphiphilic or amphipathic: Has hydrophilic part and lipophilic part

Mechanism of action Polyenes binds to hydrophobic region of ergosterol forming a hydrophilic channel creates an ion-channel Tunneling loss of essen al cell cons tuents (e.g. K+) cell death

3) What are the main structural, pharmacological, and toxicological differences between amphotericin B and nystatin? The number of conjugated double bonds (nystatin= 4; amphotericin= 7) Amphotericin B: the highest activity and the lowest toxicity

Inhibitors of Cell Membrane B- Inhibitors of ergosterol synthesis 1- Azoles Imidazoles (Clotrimazole, Miconazole, Ketoconazole) Triazoles (Itraconazole, Posaconazole, Fluconazole, Voriconazole) 2- Allylamines Terbanafine &Tolnaftate 3- Morpholines (Amorolfine) Not explained 9

Ergosterol Biosynthesis Inhibitors (1) allylamines Three enzymes can be inhibited in this pathway Squalene epoxidase Inhibitors 1. Allylamines Lanosterol 14αdemethylase Inhibitors 2. Azoles (3) Morpholines α (2) azoles 14α-CH 3 14 -Reductase Inhibitors 3. Morpholines 10

4) a) Explain the mechanism of action of azoles. Mechanism of action: Inhibition of CYP450 14α Demethylase lack of ergosterol needed for the intact membrane accumulation of lanosterolin the fungal cell membrane permeability change cell death HO 14α-Me lanosterol CYP450 14α Demethylase Azoles HO b) Why is the cholesterol synthesis in humans usuallynot affected? Cholesterol synthesis in human cells also employing 14α-demethylase but not affected due to the reduced strength of inhibition, example Ketoconazole: IC 50 (Cand. albicans enzyme) 10-9 M IC 50 (human enzyme) 10-6 M So it inhibits fungal enzyme with 1000 times more IC 50 represents the concentration of a drug needed for 50% inhibition. The lower the ic 50 the more potent the inhibitor.

Azoles N N N N H imidazole Clotrimazole Miconazole Ketoconazole N H triazole Itraconazole Posaconazole Fluconazole Voriconazole

5) a) Indicate the position of the most basic nitrogen in imidazole and triazole. Explain why using the appropriate equations. Imidazole: N 3 3 2 1 N 1 lone pair is involved in resonance, therefore not basic. Triazole: N 4 1 2 3 4 N 1 lone pair is involved in resonance. N 2 lone pair is less available due to the electron-withdrawing effect of the adjacent electronegative N 1. Protonation of the most basic nitrogen provides a stabilized conjugate acid by resonance.

5) b) Explain how the basicity of imidazole and triazole is essential for: i) the mechanism of action of azoles. The 14 α -demethylaseis a CYP450 enzyme. It has heme(iron) as co-factor. The basic imidazole/triazolenitrogen in azoles forms a bond to the hemeiron, preventing the enzyme from oxidizing (demethylating) lanosterol(available lone pair of nitrogen required for coordinate bond formation with heme). heme ii) the solubility of azoles in dilute mineral acids. Explain using the appropriate equation. Protonation of the basic nitrogen gives ionized form with higher water solubility. Imidazole or triazole Ionization increases water solubility

6) Draw the structure of clotrimazoleand outline its synthesis. Clotrimazole

Clotrimazole Synthesis Clotrimazole 16

7)a) Explain the advantages of ketoconazole over miconazole and clotrimazole. The first orally active antifungal azole. b) Explain why the oral bioavailability of ketoconazole is decreased when coadministrated with antacids or H2-antagonists. Oral bioavailability only at low stomach ph < 4, antacids and H 2 -histamine antagonists which decrease stomach acidity reduce absorption. As acid medium is required for protonation and solublization of the drug.

c) Explain why ketoconazole and amphotericin B should NOT be used together. Ketoconazole and amphotericin B should NOT be used together, because the decrease in ergosterol in the fungal membrane reduces the fungicidal action of amphotericin B.

8)a) Encircle and explain two structural differences between ketoconazole and itraconazole. extensively metabolisedto inactive metabolites (N-deacetylation) Imidazole Longer half-life Active hydroxymetabolite (omega-1 hydroxylation) Triazole

b) Give 3 advantages of itraconzoleover ketoconazole. Itraconazole Better tolerated, not hepatotoxic,no anti-androgenic effects. Generally triazolederivatives are safer More effective, Broad spectrum antifungal agent than ketoconazole Also effective against Aspergillus infections. Generally triazolederivatives are more active Longer half-life (20-30 h) than ketoconazole(6-9 h), active hydroxymetabolite Ketoconazole Inhibits the synthesis of cholesterol and other steroid hormones an androgenic effects (loss of libido gynecomastia). not effective against Aspergillus. Ketoconazoleis extensively metabolized to the inactive deacetylatedproduct

9)a) Encircle and explain three structural differences between itraconazoleand posaconazole. Which of the structural changes has the highest influence on metabolism? Tetrahydrofuran Dioxolane Posaconazole b) Why is posaconazoleexpected to have less drug interactions than itraconazoleand ketoconazole? Metabolized mainly by phase II glucoronideconjugation (not by CYP450) fewer drug interactions (no competition with other drugs for the CYP450)

Drug Drug Interactions Ketoconazole Itraconazole - Other drugs CYP 450 (phase I) CYP3A4 no competition with other drugs for the CYP450 Posaconzaole direct phase II metabolism Phase II (conj.)

10) In the structure of Itraconazole, encircle the triazolering responsible for its mechanism of action as antifungal drug. Not basic 4 Triazole: basic, binding to heme part of 14αdemethylasevia N 4 4 1,2,4-triazol-3-one: N 4 in 1,2,4-triazol-3-one has no available lone pair for coordination with hemeiron, no binding to 14α-demethylase Lone pair is involved in resonance

11) Draw the structure of fluconazole. Encircle the structural elements responsible for its water solubility. What are two major therapeutic advantage of fluconazole when compared to other azoles. Penetrates into CNS and CSF drug of choice for the treatment of cryptococcal meningitis Excellent oral bioavailability (90%), not affected by the presence of food or ph Long half-life 27-34 h HO N N F N F N N N 13) What is the major difference between fluconazole and voriconazolein terms of metabolism and activity? Fluconazole Treatmentof candidiasisand cryptococcosis Littlehepatic metabolism, excreted unchanged in the urine Voriconazole Active against Aspergillus, more potent against Candida ExtensiveCYP450 biotransformation drug interaction (methyl hydroxylation, N-oxidation)

Study Guide (tut 1) The first few lecture slides describing different types of fungal infections and their characteristics are background preparatory slides to understand the treatment but not to memorize. The exact species of Tinea infections are not to be memorized. Structures to be memorized : Clotrimazole and fluconazole. All the other structures in the tutorial and the lecture slides are to be recognized (you will be given the drug structure and you have know the name). The steps of ergosterol synthesis (slide 10) are not to be memorized but you have to know only the target enzymes names which are inhibited by the drugs. The lecture still has many drugs which are not discussed here